Skip to main content

Table 6 Summary cost-effectiveness findings in patients with P-NET

From: Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

Analysis 177Lu-Dotatate Comparator Δ
P-NET, versus octreotide LAR 60 mga
 Total costs, GBP 117,922 52,470 65,452
 Quality-adjusted life years, QALYs 4.78 2.16 2.61
 ICER, GBP per QALY gained   25,068  
P-NET versus sunitinib
 Total costs, GBP 113,423 81,303 32,119
 Quality-adjusted life expectancy, QALYs 4.88 2.92 1.96
 ICER, GBP per QALY gained   16,390  
P-NET versus everolimus
 Total costs, GBP 108,445 70,974 37,472
 Quality-adjusted life expectancy, QALYs 4.12 2.69 1.44
 ICER, GBP per QALY gained   26,103  
  1. aBased on MAIC data obtained from the placebo arm of the A6181111 trial of sunitinib [17]
  2. GI-NET gastrointestinal neuroendocrine tumor, ICER incremental cost-effectiveness ratio, LAR long-acting release, MAIC matched adjusted indirect comparison, P-NET pancreatic neuroendocrine tumor, QALY quality-adjusted life year
  3. Numerical discrepancies due to rounding